HighTower Advisors
AKBA icon

HighTower Advisors’s Akebia Therapeutics AKBA Stock Holding History

HighTower Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.3K Buy
31,144
+3,894
+14% +$5.35K ﹤0.01% 3718
2025
Q4 		$43.9K Sell
27,250
-89,850
-77% -$188K ﹤0.01% 3583
2025
Q3 		$320K Hold
117,100
– – ﹤0.01% 2994
2025
Q2 		$426K Sell
117,100
-9,000
-7% -$24.7K ﹤0.01% 2663
2025
Q1 		$242K Buy
126,100
+32,750
+35% +$66.8K ﹤0.01% 3035
2024
Q4 		$177K Hold
93,350
– – ﹤0.01% 3234
2024
Q3 		$122K Buy
93,350
+5,000
+6% +$6.68K ﹤0.01% 3264
2024
Q2 		$89K Buy
88,350
+15,000
+20% +$18.5K ﹤0.01% 3227
2024
Q1 		$135K Sell
73,350
-23,000
-24% -$36.8K ﹤0.01% 3082
2023
Q4 		$119K Buy
96,350
+1,000
+1% +$1.02K ﹤0.01% 3157
2023
Q3 		$109K Buy
95,350
+25,000
+36% +$32.1K ﹤0.01% 3082
2023
Q2 		$65K Hold
70,350
– – ﹤0.01% 3142
2023
Q1 		$40K Buy
70,350
+10,925
+18% +$8.35K ﹤0.01% 3072
2022
Q4 		$34K Buy
59,425
+7,401
+14% +$2.32K ﹤0.01% 3080
2022
Q3 		$16K Buy
52,024
+6,300
+14% +$2.47K ﹤0.01% 2985
2022
Q2 		$16K Sell
45,724
-2,958
-6% -$1.24K ﹤0.01% 3017
2022
Q1 		$35K Sell
48,682
-11
-0% -$24 ﹤0.01% 3107
2021
Q4 		$110K Hold
48,693
– – ﹤0.01% 2903
2021
Q3 		$141K Sell
48,693
-450
-0.9% -$1.28K ﹤0.01% 2797
2021
Q2 		$187K Hold
49,143
– – ﹤0.01% 2688
2021
Q1 		$167K Sell
49,143
-342
-0.7% -$1.23K ﹤0.01% 2654
2020
Q4 		$139K Sell
49,485
-2,552
-5% -$7.45K ﹤0.01% 2288
2020
Q3 		$129K Buy
52,037
+15,781
+44% +$138K ﹤0.01% 2189
2020
Q2 		$493K Buy
36,256
+450
+1% +$4.66K ﹤0.01% 1468
2020
Q1 		$271K Hold
35,806
– – ﹤0.01% 1627
2019
Q4 		$226K Buy
35,806
+18,875
+111% +$89.7K ﹤0.01% 1893
2019
Q3 		$66K Buy
16,931
+754
+5% +$3.23K ﹤0.01% 2203
2019
Q2 		$79K Buy
+16,177
New +$92K ﹤0.01% 2183

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

HighTower Advisors's AKBA Position: Q1 2026 in Review

HighTower Advisors increased its Akebia Therapeutics (AKBA) stake by 14% in Q1 2026, buying an estimated $5.35K and bringing the position to 31,144 shares worth $43.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3718.

HighTower Advisors first reported a position in AKBA in Q2 2019 and has held it in 28 quarters since. The position peaked at $493K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • HighTower Advisors held 31,144 shares of Akebia Therapeutics worth $43.3K as of Q1 2026.
  • HighTower Advisors bought 3,894 Akebia Therapeutics shares in Q1 2026, an estimated $5.35K.
  • Akebia Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3718 holding.
  • HighTower Advisors first reported a position in Akebia Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • HighTower Advisors's Akebia Therapeutics position peaked at $493K in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.